Article
Medicine, General & Internal
Sofia Tejada, Miia Jansson, Candela Sole-Lleonart, Jordi Rello
Summary: Neuraminidase inhibitors (NAIs) therapy significantly reduced the time to clinical resolution, total influenza-related complications, acute otitis media and need for antibiotic treatment. While reductions in mortality, pneumonia, asthma exacerbations, and hospitalization rates only demonstrated a trend benefit with NAIs treatment. The most significant adverse event associated with NAIs was an increase in nausea and vomiting.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Infectious Diseases
Deepali Kumar, Michael G. Ison, Jean-Paul Mira, Tobias Welte, Jick Hwan Ha, David S. Hui, Nanshan Zhong, Takefumi Saito, Laurie Katugampola, Neil Collinson, Sarah Williams, Steffen Wildum, Andrew Ackrill, Barry Clinch, Nelson Lee
Summary: This study tested the combination of baloxavir with NAIs in hospitalized patients with severe influenza but found no superior clinical outcomes compared to NAIs alone. The combination was well tolerated, suggesting that combination antivirals may not be routinely indicated in clinical practice for this patient population.
LANCET INFECTIOUS DISEASES
(2022)
Review
Medicine, General & Internal
Jen-Wei Liu, Shen-Hua Lin, Lin-Chien Wang, Hsiao-Yean Chiu, Jen-Ai Lee
Summary: This study compared the efficacy and safety of neuraminidase inhibitors and the endonuclease inhibitor for the treatment of seasonal influenza among healthy adults and children. The results showed that zanamivir was associated with the shortest time to alleviation of influenza symptoms, while baloxavir was associated with reduced rate of influenza-related complications.
Article
Pharmacology & Pharmacy
Sofia Tejada, Alexandre M. Tejo, Yolanda Pena-Lopez, Carlos G. Forero, Xavier Corbella, Jordi Rello
Summary: The study found that baloxavir and neuraminidase inhibitors (NAIs) have a significant reduction effect on complications of uncomplicated influenza, especially in reducing antibiotic prescriptions. Single-dose baloxavir is non-inferior to NAIs in terms of safety and efficacy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Environmental Sciences
Magdalena Swierczynska, Dagmara M. Mirowska-Guzel, Edyta Pindelska
Summary: This article presents the possibilities of using all available antiviral drugs specific for influenza A and B, and compares the currently recommended anti-influenza medications. It highlights the promising new drug baloxavir marboxil, and suggests further research on combination therapy.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Virology
Smriti Krishna, Anup Jayaram, Ujwal Shetty, Prasad Varamballi, Chiranjay Mukhopadhyay, Anitha Jagadesh
Summary: Influenza viruses can mutate, leading to respiratory ailments. The H275Y mutation in the neuraminidase gene reduces the effectiveness of oseltamivir, a commonly used drug for treating Influenza A and B virus infection. This study aimed to estimate the prevalence of the H275Y mutation among hospitalized patients from 2014 to 2021. The results showed a low prevalence of oseltamivir resistance and raised concerns about the effectiveness of the recommended probes for detecting the mutation in recent years.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Materials Science, Multidisciplinary
Guo-Qiang Zhang, Hao Chang, Zhiyuan Gao, Yang-ping Deng, Sheng Zeng, Luqing Shang, Dan Ding, Qian Liu
Summary: In this study, a neuraminidase-responsive, near-infrared (NIR) fluorescence probe (SA-DCM) with both ratiometric and colormetric properties was reported for various applications. The ratiometric properties of SA-DCM allowed for increased anti-interference capacity, enhanced detection accuracy, and outstanding sensitivity and selectivity. A colorimetric approach was also established using SA-DCM, allowing for direct color conversion on a cotton swab to detect neuraminidase, with simplicity and practicality as the result could be directly read by the naked eye.
ACS MATERIALS LETTERS
(2023)
Article
Pharmacology & Pharmacy
Andrei A. Ivashchenko, Jeremy C. Jones, Dmitry O. Shkil, Yan A. Ivanenkov, Philippe Noriel Q. Pascua, Melissa K. Penaflor, Ruben N. Karapetian, Elena A. Govorkova, Alexandre V. Ivachtchenko
Summary: In this study, the efficacy of a new orally-dosed neuraminidase inhibitor (NAI) AV5080 against different subtypes of influenza viruses was examined. AV5080 showed superior in vitro efficacy compared to currently approved NAIs, oseltamivir and zanamivir. However, it exhibited reduced inhibition against certain viral variants, such as NA-E119G and NA-R292K. These findings suggest that AV5080 is a promising orally-dosed NAI.
ANTIVIRAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Yulu Chen, Fei Wang, Liwei Yin, Haihai Jiang, Xishan Lu, Yuhai Bi, Wei Zhang, Yi Shi, Roberto Burioni, Zhou Tong, Hao Song, Jianxun Qi, George F. Gao
Summary: The human broadly neutralizing antibody PN-SIA28 can bind to different hemagglutinins from various influenza viruses and bat-origin hemagglutinins. Structural analysis reveals that PN-SIA28 binds to a highly conserved epitope in different hemagglutinins, providing information for the design of more potent antibodies and influenza vaccines.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Xin Liu, Thomas Balligand, Claire Carpenet, Hidde L. Ploegh
Summary: The immune system protects the body by eliminating pathogens such as viruses and bacteria. Researchers have developed a conjugate that combines the influenza neuraminidase inhibitor zanamivir with a nanobody that recognizes mouse immunoglobulin. This conjugate targets virus-infected cells and stimulates the immune system to eliminate them. It has shown effective prophylactic and therapeutic effects against influenza.
SCIENCE IMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Xuan Wei, Wenjuan Du, Margherita Duca, Guangyun Yu, Erik de Vries, Cornelis A. M. de Haan, Roland J. Pieters
Summary: Divalent inhibitors of the neuraminidase enzyme were synthesized with different spacers and the ligand Delta 4-beta-D-glucoronide showed good inhibitory potency against the Influenza A virus. The compounds also exhibited inhibition against hemagglutinin.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Virology
Yongjun Lee, Phuong Thi Hoang, Dongjun Kim, Ramadhani Qurrota Ayun, Quynh Xuan Thi Luong, Kyungho Na, Taehyun Kim, Yeonsu Oh, Won-Keun Kim, Sukchan Lee
Summary: The novel minibody 3D8 scFv shows antiviral activity against influenza A viruses by directly hydrolyzing viral RNA, leading to inhibition of viral replication. Both prophylactic and therapeutic administration of 3D8 scFv significantly increased survival rates of Oseltamivir-resistant H1N1-infected mice.
Article
Immunology
Chia-Ping Su, K. Arnold Chan, Ching-Tai Huang, Chi-Tai Fang
Summary: The study shows that inhaled zanamivir is as effective as oral oseltamivir in preventing influenza-related hospitalization or death for outpatients.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Najat Bdeir, Prerna Arora, Sabine Gaertner, Stefan Poehlmann, Michael Winkler
Summary: The presence of multiple DI RNAs derived from genomic segments encoding polymerase subunits might not result in increased antiviral activity, showing no significant impact on viral replication and interferon induction.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
JiaPing Zhou, Xue-Lin Rong, Xuan Cao, Qi Tang, Dong Liu, Yin-Hua Jin, Xiao-Xiao Shi, Ming Zhong, YueTao Zhao, Yang Yang
Summary: Biomimicry of the mucin barrier function is an efficient strategy to counteract influenza. Researchers synthesized a macromolecule that mimics the structure of mucin and demonstrated its ability to adsorb the influenza virus. The macromolecule effectively prevented viral attachment and infection, and also has potential applications in designing antiviral drugs and filtration materials.
Article
Biophysics
Masumi Ueda Oshima, Brenda M. Sandmaier, Effie Petersdorf, Mary E. Flowers, Geoffrey R. Hill, Stephanie J. Lee, Frederick R. Appelbaum, Paul A. Carpenter, K. Scott Baker, Laura Connelly-Smith, Andrea McCool, Suni Elgar, Steven A. Pergam, Catherine Liu, F. Marc Stewart, Marco Mielcarek
Summary: This article summarizes the experience gained by the Fred Hutchinson Cancer Research Center during the COVID-19 pandemic, focusing on the challenges faced and guiding principles for stem cell transplants in the pandemic setting. The article also discusses the potential impact of directing clinical resources towards COVID-19 care on cancer patients in need of stem cell transplantation.
BONE MARROW TRANSPLANTATION
(2021)
Review
Surgery
Olivia S. Kates, Erica J. Stohs, Steven A. Pergam, Robert M. Rakita, Marian G. Michaels, Cameron R. Wolfe, Lara Danziger-Isakov, Michael G. Ison, Emily A. Blumberg, Raymund R. Razonable, Elisa J. Gordon, Douglas S. Diekema
Summary: Patients undergoing solid organ transplantation should receive multiple vaccines to prevent diseases, but increasing vaccine refusal poses challenges for transplant centers. A uniform national policy addressing vaccine refusal among transplant candidates is needed to establish a consistent approach.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Immunology
Julian Lindsay, Jad Othman, Ian Kerridge, Keith Fay, William Stevenson, Chris Arthur, Sharon C-A Chen, David C. M. Kong, Steven A. Pergam, Catherine Liu, Monica A. Slavin, Matthew Greenwood
Summary: CMV reactivation is common after alloHCT, especially in D-/R+ URD recipients. This study suggests that cs-CMVi is associated with increased non-relapse mortality and that initiating preemptive therapy beyond a viral load of 250 IU/mL may be beneficial in preventing CMV-related complications.
TRANSPLANT INFECTIOUS DISEASE
(2021)
Article
Medicine, General & Internal
Laura E. Flores, Walter R. Frontera, Michele P. Andrasik, Carlos Del Rio, Antonio Mondriguez-Gonzalez, Stephanie A. Price, Elizabeth M. Krantz, Steven A. Pergam, Julie K. Silver
Summary: This study found that members of racial/ethnic minority groups and older adults were underrepresented in US-based vaccine clinical trials, while female adults were overrepresented. It is recommended that diversity enrollment targets be included in all vaccine trials targeting epidemiologically important infections.
Article
Oncology
Maresa C. Woodfield, Steven A. Pergam, Parth D. Shah
Summary: It is suggested that cocoon vaccination strategies should be used to protect cancer patients in the COVID-19 vaccination race. Medical systems specializing in cancer care should support education and vaccination campaigns targeting informal caregivers and household contacts, in addition to cancer patients.
Letter
Oncology
Christopher R. Friese, Toni K. Choueiri, Narjust Duma, Dimitrios Farmakiotis, Petros Grivas, Brian I. Rini, Dimpy P. Shah, Michael A. Thompson, Steven A. Pergam, Sanjay Mishra, Jeremy L. Warner
Editorial Material
Immunology
Steven A. Pergam, Sanjeet S. Dadwal
CLINICAL INFECTIOUS DISEASES
(2021)
Editorial Material
Immunology
Lawrence Corey
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
L. Corey, P. B. Gilbert, M. Juraska, D. C. Montefiori, L. Morris, S. T. Karuna, S. Edupuganti, N. M. Mgodi, A. C. deCamp, E. Rudnicki, Y. Huang, P. Gonzales, R. Cabello, C. Orrell, J. R. Lama, F. Laher, E. M. Lazarus, J. Sanchez, I. Frank, J. Hinojosa, M. E. Sobieszczyk, K. E. Marshall, P. G. Mukwekwerere, J. Makhema, L. R. Baden, J. I. Mullins, C. Williamson, J. Hural, M. J. McElrath, C. Bentley, S. Takuva, M. M. Gomez Lorenzo, D. N. Burns, N. Espy, A. K. Randhawa, N. Kochar, E. Piwowar-Manning, D. J. Donnell, N. Sista, P. Andrew, J. G. Kublin, G. Gray, J. E. Ledgerwood, J. R. Mascola, M. S. Cohen
Summary: The study found that broadly neutralizing antibodies did not prevent HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates indicated that prophylaxis with broadly neutralizing antibodies may be effective.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Immunology
Michael G. Ison, Robin Avery, Emily Blumberg, Peter Chin-Hong, Natasha Halasa, Dan Kaul, Steve Pergam, Nicole M. Theodoropoulos, Cameron R. Wolfe
Article
Medicine, General & Internal
Dean Follmann, Holly E. Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen Kotloff, Michael Desjardins, Lawrence Corey, Kathleen M. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, Lindsey R. Baden
Summary: This study evaluated the seropositivity of anti-nucleocapsid antibody (anti-N Ab) in mRNA-1273 vaccinees with breakthrough SARS-CoV-2 infection. The results showed a lower seroconversion rate in vaccinees, indicating the importance of considering vaccination status when interpreting seroprevalence and seropositivity data based solely on anti-N Ab testing.
ANNALS OF INTERNAL MEDICINE
(2022)
Review
Immunology
Corey Casper, Lawrence Corey, Jeffrey Cohen, Blossom Damania, Anne A. Gershon, David C. Kaslow, Laurie T. Krug, Jeffrey Martin, Sam M. Mbulaiteye, Edward S. Mocarski, Patrick S. Moore, Javier Gordon Ogembo, Warren Phipps, Denise Whitby, Charles Wood
Summary: This article summarizes the epidemiology and biology of Kaposi sarcoma herpesvirus (KSHV) as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
Article
Medicine, Research & Experimental
Daniel Corey, Francoise Haeseleer, Joe Hou, Lawrence Corey
Summary: Adoptive therapy using genetically engineered T cells shows promise in treating infectious diseases in immunocompromised individuals. In this study, chimeric engulfment receptor (CER) T cells designed to recognize phosphatidylserine (PS)-expressing cells successfully eliminated SIV-infected cells. The introduction of innate immune functions into T cells enhances the elimination of SIV-infected cells, and further in vivo studies are needed to evaluate their effectiveness.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2023)
Article
Immunology
Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda-Gail Bekker, Mina Hosseinipour, Sinead Delany-Moretlwe
Summary: This study used counterfactual placebo comparisons using other data sources to evaluate the efficacy of antiretroviral agents for HIV pre-exposure prophylaxis. The findings showed that injectable cabotegravir (CAB-LA) and daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can significantly reduce the risk of HIV infection compared to no intervention, and the efficacy of FTC/TDF against counterfactual placebo was consistent with previous placebo-controlled trials.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2023)
Article
Medicine, Research & Experimental
Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck, Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, Ian Hirsch
Summary: AZD1222 vaccine demonstrated safety, efficacy, and immunogenicity in the ongoing phase 3 trial. The vaccine provided durable protection with a significant reduction in the incidence of symptomatic COVID-19 and showed high efficacy against severe/critical disease. Humoral immune responses induced by AZD1222 waned over time.
JOURNAL OF CLINICAL INVESTIGATION
(2022)